QLGN

Qualigen Therapeutics Inc

QLGN, USA

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.

https://qlgntx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
QLGN
stock
QLGN

How QLGN stock valuations compare to rivals - July 2025 Macro Moves & Daily Stock Momentum Reports moha.gov.vn

Read more →
QLGN
stock
QLGN

Jia Yueting-backed listed company QLGN has been renamed AIxCrypto and will launch stock tokenization business Bitget

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$5

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

1.13

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.11

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-5.29 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-4.69 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.13

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.06% of the total shares of Qualigen Therapeutics Inc

1.

LLBH Private Wealth Management, LLC

(0.5898%)

since

2025/06/30

2.

Fidelity Extended Market Index

(0.2299%)

since

2025/07/31

3.

Fidelity Series Total Market Index

(0.0805%)

since

2025/07/31

4.

Tower Research Capital LLC

(0.0701%)

since

2025/06/30

5.

BlackRock Inc

(0.0301%)

since

2025/06/30

6.

HARBOUR INVESTMENTS, INC.

(0.0192%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0185%)

since

2025/07/31

8.

State St US Extended Mkt Indx NL Cl C

(0.0048%)

since

2025/08/31

9.

NT Ext Equity Mkt Idx Fd - L

(0.0025%)

since

2025/06/30

10.

Northern Trust Extended Eq Market Idx

(0.0025%)

since

2025/06/30

11.

NT Ext Equity Mkt Idx Fd - NL

(0.0022%)

since

2025/06/30

12.

SSgA U.S. Total Market Index Strategy

(0.002%)

since

2025/03/31

13.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0018%)

since

2025/06/30

14.

BNYM Mellon SL Market Completion UC1

(0.0016%)

since

2025/06/30

15.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0007%)

since

2025/06/30

16.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0006%)

since

2024/12/31

17.

Group One Trading, LP

(0.0005%)

since

2025/06/30

18.

U.S. Bancorp

(0.0004%)

since

2025/06/30

19.

Bank of America Corp

(0.0004%)

since

2025/06/30

20.

State St US Ttl Mkt Indx NL Cl A

(0.0004%)

since

2025/08/31

21.

Northern Trust Wilshire 5000

(0.0003%)

since

2025/06/30

22.

Uma Financial Services Inc

(0.0001%)

since

2025/06/30

23.

SBI Securities Co Ltd

(0.0001%)

since

2025/06/30

24.

BNYM Mellon NSL Mkt Completion Fund Inst

(0.0001%)

since

2025/06/30

25.

UBS Group AG

(0%)

since

2025/03/31

26.

FNY Investment Advisers, LLC

(0%)

since

2025/06/30

28.

JPMorgan Chase & Co

(0%)

since

2025/03/31

29.

Advisor Group Holdings, Inc.

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-1.0019

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(9.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(3)
Value
Undervalued(8)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.